U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002502) titled 'Immune Modulation With PRaG-1 Treatment' on May 25.
Brief Summary: The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
Cancer
Solid Cancer
Intervention:
D...